Replies to post #238915 on Biotech Values

[DewDiligence]

Was nobody else wowed by the blowout 2Q21 Botox numbers? Evidently, ABBV is every bit as good at promoting Botox as standalone Allergan was.

[DewDiligence]

3Q21 worldwide Botox sales=$1.19B, flat QoQ*, +30% YoY†:

https://news.abbvie.com/news/press-releases/abbvie-reports-third-quarter-2021-financial-results.htm

• US therapeutic: $534M (+9% QoQ*, +24% YoY†)
• US cosmetic: $356M (-3% QoQ*, +50% YoY†)
--
US total: $880M (61% therapeutic; 39% cosmetic) was 75% of worldwide total


• Ex-US therapeutic: $111M (-1 QoQ*, +14% YoY†)
• Ex-US cosmetic: $189M (-13% QoQ*, +18% YoY†)
--
Ex-US total: $300M (37% therapeutic; 63% cosmetic) was 25% of worldwide total


*Botox sales are seasonally stronger during the second and fourth calendar quarters than the first and third calendar quarters.

†YoY growth rates are exaggerated due to the effect of the pandemic in 2020.